Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of Ralmitaront (RO6889450) in Healthy Volunteers
NCT02699372Phase 1Completed
- Sponsor
- Roche
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ralmitaront in schizophrenia (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities After Single Ascending Dose up to 22 days, Area Under the Curve from Time Zero to end of dosing interval After Multiple Oral Ascending Doses at Day 14 and 5 more. Started Mar 2016; status: completed.
02
Drugs
ralmitaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02699372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699372.